Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acorda Enacts 'Poison Pill' In Effort To Stave Off Scopia

Executive Summary

After the hedge fund Scopia called on Acorda to investigate the possibility of a sale, the biotech's argument for its current direction faltered due to an FDA refuse-to-file letter for Inbrija. Acorda then adopted a shareholder rights plan to buy time.


Related Content

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie
Acorda Investor Scopia Seeks Big Return From Sale Of The Company
Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up
Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation
Deep Breath For Acorda As It Prepares Inhaled Levodopa Filing


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts